|
Market Closed -
Other stock markets
|
After hours 05:30:00 am | |||
| 363.34 USD | -0.55% |
|
352.09 | -3.10% |
| 03/06 | Waters Corporation Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 10:30 AM | |
| 03/06 | Waters Corporation Announces FDA 510(k) Clearance Of BD BACTEC FXI Culture System | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 278.59Cr | 297.2Cr | 295.64Cr | 295.84Cr | 316.53Cr | |||||
Total Revenues | 278.59Cr | 297.2Cr | 295.64Cr | 295.84Cr | 316.53Cr | |||||
Cost of Goods Sold, Total | 115.65Cr | 124.82Cr | 119.52Cr | 120.02Cr | 128.88Cr | |||||
Gross Profit | 162.93Cr | 172.38Cr | 176.12Cr | 175.82Cr | 187.65Cr | |||||
Selling General & Admin Expenses, Total | 63Cr | 66Cr | 70Cr | 69Cr | 75Cr | |||||
R&D Expenses | 17Cr | 18Cr | 17Cr | 18Cr | 20Cr | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 71.43L | 63.66L | 3.26Cr | 4.71Cr | 4.78Cr | |||||
Other Operating Expenses, Total | 80Cr | 84Cr | 90Cr | 92Cr | 99Cr | |||||
Operating Income | 83Cr | 88Cr | 86Cr | 84Cr | 89Cr | |||||
Interest Expense, Total | -4.49Cr | -4.88Cr | -9.89Cr | -8.97Cr | -6.95Cr | |||||
Interest And Investment Income | 1.22Cr | 1.1Cr | 1.66Cr | 1.74Cr | 1.88Cr | |||||
Net Interest Expenses | -3.27Cr | -3.78Cr | -8.22Cr | -7.23Cr | -5.08Cr | |||||
Other Non Operating Income (Expenses) | -26.7L | 8L | 11.37L | 11.71L | 28.38L | |||||
EBT, Excl. Unusual Items | 79Cr | 85Cr | 78Cr | 77Cr | 84Cr | |||||
Restructuring Charges | - | - | -2.6Cr | - | - | |||||
Merger & Related Restructuring Charges | - | - | -1.3Cr | - | -8.5Cr | |||||
Gain (Loss) On Sale Of Investments | 1Cr | 10L | - | - | - | |||||
Asset Writedown | - | - | - | - | - | |||||
In Process R&D Expenses | - | -97.97L | - | - | - | |||||
Legal Settlements | 48.35L | - | - | -1.16Cr | - | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 81Cr | 84Cr | 74Cr | 75Cr | 75Cr | |||||
Income Tax Expense | 11Cr | 13Cr | 9.4Cr | 12Cr | 11Cr | |||||
Earnings From Continuing Operations | 69Cr | 71Cr | 64Cr | 64Cr | 64Cr | |||||
Net Income to Company | 69Cr | 71Cr | 64Cr | 64Cr | 64Cr | |||||
Net Income - (IS) | 69Cr | 71Cr | 64Cr | 64Cr | 64Cr | |||||
Net Income to Common Incl Extra Items | 69Cr | 71Cr | 64Cr | 64Cr | 64Cr | |||||
Net Income to Common Excl. Extra Items | 69Cr | 71Cr | 64Cr | 64Cr | 64Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 11.25 | 11.8 | 10.87 | 10.75 | 10.8 | |||||
Basic EPS - Continuing Operations | 11.25 | 11.8 | 10.87 | 10.75 | 10.8 | |||||
Basic Weighted Average Shares Outstanding | 6.16Cr | 6Cr | 5.91Cr | 5.93Cr | 5.95Cr | |||||
Net EPS - Diluted | 11.17 | 11.73 | 10.84 | 10.71 | 10.76 | |||||
Diluted EPS - Continuing Operations | 11.17 | 11.73 | 10.84 | 10.71 | 10.76 | |||||
Diluted Weighted Average Shares Outstanding | 6.2Cr | 6.03Cr | 5.93Cr | 5.96Cr | 5.97Cr | |||||
Normalized Basic EPS | 8.03 | 8.82 | 8.2 | 8.07 | 8.82 | |||||
Normalized Diluted EPS | 7.97 | 8.77 | 8.17 | 8.04 | 8.79 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 96Cr | 101.41Cr | 102.23Cr | 102.94Cr | 109.4Cr | |||||
EBITA | 89Cr | 94Cr | 94Cr | 94Cr | 100.59Cr | |||||
EBIT | 83Cr | 88Cr | 86Cr | 84Cr | 89Cr | |||||
EBITDAR | 99Cr | 105.01Cr | 106.03Cr | 106.84Cr | 113.5Cr | |||||
Total Revenues (As Reported) | 278.59Cr | 297.2Cr | 295.64Cr | 295.84Cr | 316.53Cr | |||||
Effective Tax Rate - (Ratio) | 14.06 | 15.53 | 12.77 | 15.5 | 14.87 | |||||
Current Domestic Taxes | 2Cr | 7.02Cr | 66.05L | 2.7Cr | 1.38Cr | |||||
Current Foreign Taxes | 7.67Cr | 9.19Cr | 8.86Cr | 9.09Cr | 11Cr | |||||
Total Current Taxes | 9.67Cr | 16Cr | 9.52Cr | 12Cr | 13Cr | |||||
Deferred Domestic Taxes | 1.08Cr | -3.1Cr | -54.86L | -80T | -1.91Cr | |||||
Deferred Foreign Taxes | 57.97L | -10.17L | 42.89L | -8L | 44.6L | |||||
Total Deferred Taxes | 1.66Cr | -3.2Cr | -11.97L | -9L | -1.47Cr | |||||
Normalized Net Income | 49Cr | 53Cr | 48Cr | 48Cr | 52Cr | |||||
Non-Cash Pension Expense | 6L | -19T | 65T | 2L | -4L | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 70L | 70L | 70L | 60L | - | |||||
Selling and Marketing Expenses | 70L | 70L | 70L | 60L | - | |||||
Research And Development Expense From Footnotes | 17Cr | 19Cr | 17Cr | 18Cr | 20Cr | |||||
Net Rental Expense, Total | 3.4Cr | 3.6Cr | 3.8Cr | 3.9Cr | 4.1Cr | |||||
Imputed Operating Lease Interest Expense | 78.75L | 85.82L | 1.46Cr | 1.34Cr | 1.41Cr | |||||
Imputed Operating Lease Depreciation | 2.61Cr | 2.74Cr | 2.34Cr | 2.56Cr | 2.69Cr | |||||
Stock-Based Comp., COGS (Total) | 25L | 34.98L | 20.14L | 25.87L | 35.39L | |||||
Stock-Based Comp., R&D Exp. (Total) | 56.91L | 68.74L | 38.42L | 59.62L | 78.46L | |||||
Stock-Based Comp., SG&A Exp. (Total) | 2.17Cr | 3.22Cr | 3.1Cr | 3.62Cr | 4.27Cr | |||||
Total Stock-Based Compensation | 2.99Cr | 4.26Cr | 3.69Cr | 4.47Cr | 5.41Cr |
- Stock Market
- Stocks
- WAT Stock
- Financials Waters Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















